

KORGLUTIDE

A NEW BREAKTHROUGH
ORAL GLP-1 PEPTIDE
FOR WEIGHT LOSS

Presented by
Dr. Chung, Yongji
Founder

CAREGEN






Disclaimer

This material is intended solely to provide information to investors and international business partners, and is not intended for product promotion or to influence prescribing decisions.

All forward-looking statements included herein are subject to risks and uncertainties that may cause actual results to differ materially from expectations.

Such statements reflect Caregen's current views as of the date of this presentation, and the company undertakes no obligation to update them. All trademarks mentioned are the property of their respective owners. Caregen does not guarantee the accuracy or completeness of the information contained in this document.





Human Clinical Study Design

A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy and Safety of **Korglutide** in Weight Management in **Obese Individuals with and without Type 2 Diabetes**.

- **Subject** : Non-diabetic cohort: BMI ≥ 30 kg/m² / Diabetic cohort (Type 2 Diabetes): BMI ≥ 27 kg/m²
- **Number** : Placebo: 50, Korglutide:50
- **Statistical analysis** : One-way ANOVA /Dunnett's multiple comparisons test
- **Period** : 12-week
- **Dosage** : a daily oral dose of 100 mg.
- **Diet restriction** : 500 kcal/day, 30 min light walking (recommended)

✓ Primary Endpoint

The percentage reduction in body weight from baseline to week 12.

✓ Secondary Endpoints

Included changes in body mass index (**BMI**), **body fat mass**, **skeletal muscle mass**, **HbA1c**, and lipid profile (**including cholesterol, LDL, HDL, triglycerides**), as well as the proportion of subjects achieving **$\geq 5\%$** and **$\geq 10\%$** weight loss.





Human Clinical Study Results for Weight Loss

Body Weight Loss:

-10.78% in 12 weeks

Statistical significance: $p < 0.0001$

✓ Obese Individuals with and without Type 2 Diabetes

Statistic	Korglutide	Placebo
LS mean (SE)	-10.78% (-9.3kg)	-4.33% (-3.70kg)
LS mean Difference from Placebo	-6.45% (-5.59kg)	
P value	< 0.0001	



✓ Obese

Statistic	Korglutide	Placebo
LS mean (SE)	-10.86% (-9.57kg)	-4.42% (-3.87kg)
LS mean Difference from Placebo	-6.44% (-5.69kg)	
P value	< 0.0001	

✓ Obese with Type II Diabetes

Statistic	Korglutide	Placebo
LS mean (SE)	-10.7% (-9.03kg)	-4.25% (-3.54kg)
LS mean Difference from Placebo	-6.45% (-5.49kg)	
P value	< 0.0001	

The Comparison Korglutide with Lira/Semaglutide

Drug name	CAREGEN-K	SAXENDA	WEGOVY
Ingredient Name	Korglutide	Liraglutide	Semaglutide
Dosage and administration	<p>Oral administration</p> <p>(30mg ~ 100mg) 70mg daily, administer at any time of day, with or without meals</p>	<p>Subcutaneous injection</p> <p>(0.6mg ~ 6mg) 3mg daily, administer at any time of day, without regard to the timing of meals -initiate at 0.6mg per day for one week. In weekly intervals, increase the dose until a dose of 3mg is reached.</p>	<p>Subcutaneous injection</p> <p>(0.25mg ~ 2.4mg) 2.4mg Once weekly, on the same day each week, at any time of day, with or without meals - Initiate at 0.25mg once weekly for 4 weeks. In 4 week intervals, increase the dose until a dose of 2.4mg is reached</p>
Indications and usage	BMI 27Kg/m ² or greater (overweight) or 27kg/m ² or greater in the presence of at least one weight-related comorbid condition (Hypertension, Type2 diabetes mellitus or dyslipidemia)	BMI 30Kg/m ² or greater (obese) or 27kg/m ² or greater (overweight) in the presence of at least one weight-related comorbid condition (Hypertension, Type2 diabetes mellitus or dyslipidemia)	BMI 30Kg/m ² or greater (obese) or 27kg/m ² or greater (overweight) in the presence of at least one weight-related comorbid condition (Hypertension, Type2 diabetes mellitus or dyslipidemia)
Adverse reactions	No Adverse reactions	Nausea, hypoglycemia, diarrhea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain and increased lipase	Nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease
Structural Formula	7 Amino Acids	 <p>31 Amino Acids</p>	 <p>31 Amino Acids</p>

Korglutide's Strategic Market Positioning

Korglutide: Creating the Hybrid Category Between Rx & Supplements



*Scientific
Foundation*




Korglutide



**GLP-1 Drugs
(injectable, Rx)**

**Weight-Loss
Supplement**

Accessibility



Korglutide : New Weight Management Solution

Drug-like efficacy, supplement-like accessibility


Korglutide



Source: Grandview research

The World is Getting Heavier - Korglutide is Ready !

Global Obesity, Local Solutions - Korglutide Goes Worldwide.




-  < 5%
-  5-10%
-  10-20%
-  20-30%
-  ≥ 30%

Obesity BMI ≥ 30 kg/m²



We Don't Just Add Years, We Redesign Longevity



Neovert® Dermaheal
Patented Cutting Edge Biomaterials

Pim-Pim-Paul

REVOFIL

DR.CYJ DR.CYJ DR.CYJ
HAIR FILLER IDR PDR

PURILUX
WHITENING

Pelo Baum CG Dimono™ PROSTROLANE
HAIR REVITALIZING



CAREGEN



Q&A
Q&A

ASK ME
QUESTION

KORGLUTIDE

A NEW BREAKTHROUGH
ORAL GLP-1 PEPTIDE
FOR WEIGHT LOSS

We Don't Just Add Years,
We Redesign Longevity

